Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported Total Revenue of $3.07 billion for fiscal year 2025.
WEST PHARMACEUTICAL SERVICES INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.07B +6.3% |
$2.89B -1.9% |
$2.95B +2.2% |
$2.89B +2.0% |
$2.83B +31.9% |
$2.15B +16.7% |
| Revenue (ASC 606) | $3.07B +6.3% |
$2.89B -1.9% |
$2.95B +2.2% |
$2.89B +2.0% |
$2.83B +31.9% |
$2.15B +16.7% |
| Net Income | $493.70M +0.2% |
$492.70M -17.0% |
$593.40M +1.3% |
$585.90M -11.5% |
$661.80M +91.2% |
$346.20M +43.2% |
| Diluted EPS | $6.79 +1.5% |
$6.69 -15.1% |
$7.88 +1.9% |
$7.73 -10.8% |
$8.67 +89.7% |
$4.57 +42.4% |
| Total Assets | $4.27B +17.2% |
$3.64B -4.9% |
$3.83B +5.9% |
$3.62B +9.1% |
$3.31B +18.6% |
$2.79B +19.3% |
| Cash and Equivalents | $791.30M +63.3% |
$484.60M -43.2% |
$853.90M -4.5% |
$894.30M +17.3% |
$762.60M +23.9% |
$615.50M +40.2% |
| Long-Term Debt | $202.80M +0.1% |
$202.60M +178.3% |
$72.80M -64.8% |
$206.70M -1.0% |
$208.80M -17.4% |
$252.90M -0.8% |
| Stockholders Equity | $3.18B +18.4% |
$2.68B -6.9% |
$2.88B +7.3% |
$2.68B +15.0% |
$2.34B +25.9% |
$1.85B +17.9% |
| R&D Expense | $74.30M +7.5% |
$69.10M +1.0% |
$68.40M +16.9% |
$58.50M +10.8% |
$52.80M +12.6% |
$46.90M +20.6% |
| Operating Income | $584.90M +2.6% |
$569.90M -15.7% |
$676.00M -7.9% |
$734.00M -2.4% |
$752.30M +84.9% |
$406.90M +37.2% |
| Gross Profit | $1.10B +10.6% |
$998.50M -11.6% |
$1.13B -0.6% |
$1.14B -3.4% |
$1.18B +53.1% |
$767.80M +26.8% |
| Shares Outstanding | 72.00M -0.4% |
72.30M -1.6% |
73.50M -0.8% |
74.10M -0.1% |
74.20M +0.3% |
74.00M -0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $804.60M | +7.7% | +5.0% |
| Revenue (ASC 606) | September 30, 2025 | $804.60M | +7.7% | +5.0% |
| Net Income | September 30, 2025 | $140.00M | +2.9% | +6.2% |
| Diluted EPS | September 30, 2025 | $1.92 | +3.8% | +5.5% |
| Total Assets | September 30, 2025 | $4.11B | +11.7% | +3.9% |
| Cash and Equivalents | September 30, 2025 | $628.50M | +28.0% | +23.3% |
| Long-Term Debt | September 30, 2025 | $202.70M | +0.0% | +0.0% |
| Stockholders Equity | September 30, 2025 | $3.05B | +10.9% | +4.2% |
| R&D Expense | September 30, 2025 | $17.10M | +10.3% | -10.5% |
| Operating Income | September 30, 2025 | $167.60M | +3.9% | +9.0% |
| Gross Profit | September 30, 2025 | $294.30M | +11.2% | +7.4% |
| Shares Outstanding | September 30, 2025 | 71.90M | -0.8% | +0.0% |
- WEST PHARMACEUTICAL SERVICES INC reported Total Revenue of $3.07 billion for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +6.3% in Total Revenue compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Revenue (ASC 606) of $3.07 billion for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +6.3% in Revenue (ASC 606) compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Net Income of $493.70 million for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +0.2% in Net Income compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Diluted EPS of $6.79 per share for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +1.5% in Diluted EPS compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Total Assets of $4.27 billion for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +17.2% in Total Assets compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Cash and Equivalents of $791.30 million for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +63.3% in Cash and Equivalents compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Long-Term Debt of $202.80 million for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +0.1% in Long-Term Debt compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Stockholders Equity of $3.18 billion for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +18.4% in Stockholders Equity compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported R&D Expense of $74.30 million for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +7.5% in R&D Expense compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Operating Income of $584.90 million for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +2.6% in Operating Income compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Gross Profit of $1.10 billion for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +10.6% in Gross Profit compared to the prior fiscal year.
- WEST PHARMACEUTICAL SERVICES INC reported Shares Outstanding of 72.00 million shares for fiscal year 2025.
- WEST PHARMACEUTICAL SERVICES INC showed a decrease of -0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: